Previous 10 | Next 10 |
Amarin Corporation plc (AMRN) Piper Sandler 32nd Annual Virtual Healthcare Conference Dec 02, 2020, 10:00 AM ET Company Participants John Thero - President & CEO Conference Call Participants Yasmeen Rahimi - Piper Sandler Presentation Yasmeen Rahimi Thank you for joining our live Fireside...
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today the filing of a patent infringement lawsuit by Amarin affiliates and a licensor against Hikma Pharmaceuticals PLC and Hikma’s U.S. affiliate. The lawsuit was...
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to participate in a Fireside Chat at the Piper Sandler’s 32 nd Annual Hea...
Amarin lost its generic appeal and the stock has faltered badly. People are possibly ignoring the vast European market and also what's left of the US market may be protected by manufacturing hurdles. Amarin at current prices is a high risk-reward opportunity over a period of 2-3 y...
Amarin's legal loss at the U.S. appeals court sent the stock lower. Positive clinical data from China partner a catalyst. 75% upside in Amarin stock explained. For further details see: Buy Amarin And Bet On Its Recovery In 2021
My family's portfolios are filled with internet retailers that are skyrocketing, Software-as-a-Service stocks that are soaring, and one vaccine biotech that has jumped 2,000%. It's my first year writing for The Motley Fool, and simultaneously the best year of my 20-year investing career. Bu...
Ayro (AYRO) +28%.Ideanomics (IDEX) +22%.Precision BioSciences (DTIL) +19% after co. enters into a research and license agreement with LLY.Mesoblast Limited (MESO) +17% after entering into an exclusive worldwide license and collaboration agreement with Novartis.Waitr Holdin...
Amarin (AMRN) jumps 23% after-hours after sharing positive top-line results from Protocol Number EDPC003R01, a Phase 3 clinical trial of Vascepa (icosapent ethyl) conducted in China by partner, Edding.The study, which investigated Vascepa as a treatment for patients with very high t...
Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol ( LDL-C ) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per Day Dose of Icosapent Ethyl in Chinese Patien...
Amarin Corporation PLC (AMRN) Jefferies Virtual London Healthcare Conference November 19, 2020, 09:40 ET Company Participants John Thero - President, CEO & Director Conference Call Participants Michael Yee - Jefferies Presentation Michael Yee Everybody, good morning, good afternoon, depen...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...